Infant, Premature Clinical Trial
Official title:
Prospective Evaluation of the Efficacy of Palivizumab Administration in Children Born at 29-32 Weeks of Gestation
Protocol Synopsis: There is a link between early RSV infection and chronic respiratory
morbidity.
Hypothesis: Palivizumab administration may result in decreased AHR and lower respiratory
morbidity.
Primary objective: to evaluate prospectively the effect of palivizumab on airway reactivity
(AHR) in children born at 29-32 weeks.
Secondary objective: to assess prospectively the effect of palivizumab on respiratory
morbidity airway inflammation and allergy in children born at 29-32 weeks.
Inclusion criteria: premature babies 29-32 weeks of gestation born during 2007 and 2010.
Exclusion criteria: Any mechanical ventilation or chronic diseases, e.g., bronchopulmonary
dysplasia (BPD), cystic fibrosis (CF), congenital heart disease, congenital anomalies, known
immunodeficiency, or receipt of other RSV investigative vaccines or therapies.
Primary end points: Airway reactivity as assessed by methacholine challenge test with
determination of PC20.
Secondary end points: Respiratory morbidity as assessed by questionnaire and telephone
interviews. Additionally, IGE, eosinophil count, and exhaled NO will be evaluated.
Sample size: 74 participants; Group I - 37 premature babies at 29-32 weeks of gestation born
during 2007-2008 (before approval of Synagis for this group in Israel). Group II - 37
premature babies 29-32 weeks of gestation born during 2009-2010 (after approval of Synagis
for this group in Israel).
Statistics: A sample size of 37 patients was calculated as necessary to detect a difference
of 0.5 SD in AHR for a 2-sided tail, with a power of 80%. Demographics and baseline
characteristics will be compared using 1-way analysis of variance for quantitative variables
and Fisher's exact test for categorical variables.
Protocol Synopsis: There is a link between early RSV infection and chronic respiratory
morbidity.
Hypothesis: Palivizumab administration may result in decreased AHR and lower respiratory
morbidity.
Primary objective: to evaluate prospectively the effect of palivizumab on airway reactivity
(AHR) in children born at 29-32 weeks.
Secondary objective: to assess prospectively the effect of palivizumab on respiratory
morbidity airway inflammation and allergy in children born at 29-32 weeks.
Inclusion criteria: premature babies 29-32 weeks of gestation born during 2007 and 2010.
Exclusion criteria: Any mechanical ventilation or chronic diseases, e.g., bronchopulmonary
dysplasia (BPD), cystic fibrosis (CF), congenital heart disease, congenital anomalies, known
immunodeficiency, or receipt of other RSV investigative vaccines or therapies.
Primary end points: Airway reactivity as assessed by methacholine challenge test with
determination of PC20.
Secondary end points: Respiratory morbidity as assessed by questionnaire and telephone
interviews. Additionally, IGE, eosinophil count, and exhaled NO will be evaluated.
Sample size: 74 participants; Group I - 37 premature babies at 29-32 weeks of gestation born
during 2007-2008 (before approval of Synagis for this group in Israel). Group II - 37
premature babies 29-32 weeks of gestation born during 2009-2010 (after approval of Synagis
for this group in Israel).
Statistics: A sample size of 37 patients was calculated as necessary to detect a difference
of 0.5 SD in AHR for a 2-sided tail, with a power of 80%. Demographics and baseline
characteristics will be compared using 1-way analysis of variance for quantitative variables
and Fisher's exact test for categorical variables..
;
Observational Model: Case Control, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03146351 -
The Effects of Family Centered Intervention Program on Preterm Infants
|
N/A | |
| Completed |
NCT02064712 -
Determining an Optimal Weaning Method of Nasal Continuous Positive Airway Pressure in Preterm Neonates
|
N/A | |
| Completed |
NCT00365703 -
Nasogastric Tube vs. Orogastric Feeding Tube in Preterm Infants: Which is Best?
|
N/A | |
| Terminated |
NCT00179933 -
The Impact of Implementing NIDCAP on Preterm Infants in the NICU
|
N/A | |
| Completed |
NCT00114543 -
Trial of Aggressive Versus Conservative Phototherapy in Infants <1,000 Grams Birth Weight
|
Phase 3 | |
| Terminated |
NCT05030012 -
Maintaining Optimal HVNI Delivery Using Automatic Titration of Oxygen in Preterm Infants
|
N/A | |
| Completed |
NCT00552383 -
The Edmonton Randomised Controlled Trial of NIDCAP - Based Developmental Care
|
N/A | |
| Completed |
NCT00011362 -
Dexamethasone Therapy in VLBW Infants at Risk of CLD
|
Phase 3 | |
| Completed |
NCT06308471 -
Effect of Baby Massage on Oral Motor Skills of Premature Babies
|
N/A | |
| Completed |
NCT01863043 -
Aspiration of Residual Gastric Contents
|
N/A | |
| Completed |
NCT05462509 -
Feasibility of Use of the PATH bCPAP and Oxygen Blenders Device With Neonates in Uganda
|
N/A | |
| Not yet recruiting |
NCT06109350 -
The Effect of Physical Therapy Intervention on Motor Performance in Bhutanese Preterm Infants
|
N/A | |
| Completed |
NCT03551600 -
Splanchnic and Renal Tissue Oxygenation During Enteral Feedings in Neonates With Patent Ductus Arteriosus
|
||
| Terminated |
NCT02599545 -
Testosterone and Cortisol Levels in Infants
|
||
| Completed |
NCT02611284 -
Less Invasive Beractant Administration in Preterm Infants
|
N/A | |
| Completed |
NCT01193270 -
Vitamin E for Extremely Preterm Infants
|
Phase 1 | |
| Withdrawn |
NCT00536445 -
Use of NAVA in Intubated Preterm
|
Phase 1/Phase 2 | |
| Completed |
NCT00455169 -
Influenza Vaccine in Premature Infants
|
Phase 4 | |
| Completed |
NCT00579553 -
Comparing IM vs. Vaginal Progesterone for Pre-term Birth
|
N/A | |
| Completed |
NCT01203423 -
Persistent Pulmonary Hypertension of the Newborn (PPHN) Observational Study
|